Disopyramide is a class 1A antiarrhythmic agent used to treat life-threatening ventricular arrhythmias. A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine.
- Mechanism
- Curator reviewed
Disopyramide is a Type 1A antiarrhythmic drug (ie, similar to procainamide and quinidine). It inhibits the fast sodium channels. In animal studies Disopyramide decreases the rate of diastolic depolarization (phase 4) in cells with augmented automaticity, decreases the upstroke velocity (phase 0) and increases the action potential duration of normal cardiac cells, decreases the disparity in refractoriness between infarcted and adjacent normally perfused myocardium, and has no effect on alpha- or beta-adrenergic receptors.
- Primary indication
- For the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, ventricular pre-excitation and cardiac dysrhythmias.Curator reviewed · 1 structured indication
- Formula / weight
- C21H29N3O · 339.4745 g/mol (avg)
- First approval
- Canada, 2003 · United States, 1977
- Brand names
Resolves to
UVTNFZQICZKOEM-UHFFFAOYSA-NSMILESCC(C)N(CCC(C(N)=O)(C1=CC=CC=C1)C1=NC=CC=C1)C(C)CWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Disopyramide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account